Follow us on

Q of the week

Q: How Do You Get Shingles?

Get the Answer: 

Crohn's disease

Crohn's disease is an ongoing condition that causes inflammation of the digestive tract, or the GI (gastrointestinal) tract (the gut).
 Forums
Board Index Latest Posts Welcome Guest   [Register]  [Login]
EFGCP–EUCROF Joint Workshop Final Report   by  on 2010-08-20 20:12:20
Managing Clinical Trials   by  on 2010-07-16 00:05:32
US-FDA issues Revised Info Sheet Guidance on Clinical Investigator Disqualification   by  on 2010-06-13 18:11:41
US-FDA issues final guidance on Statement of Investigator (Form FDA 1572)   by  on 2010-06-13 18:07:59
Rising Clinical Trial Complexity Continues to Vex Drug Developers   by  on 2010-06-03 17:36:33
Investigator-Driven Clinical Trials: An ESF Forward Look   by  on 2010-06-03 17:27:58
NIH's Financial Conflict of Interest (FCOI) Proposed Rule   by  on 2010-05-27 19:42:00
AAP’s Guidelines for the Ethical Conduct of Studies to Evaluate Drugs in Pediatric Population   by  on 2010-05-13 19:39:54
Argentina: ANMAT - new regulatory update   by  on 2010-05-01 09:40:32
The Wall Street Journal's special supplement on clinical trials   by  on 2010-05-01 09:31:52
Major developments in EU Clinical Trial Guidances   by  on 2010-04-21 03:10:55
Analysis of the adverse reactions induced by natural product-derived drugs   by  on 2010-04-19 07:16:06
Newer Antibacterial Drugs for a New Century   by  on 2010-04-19 06:49:47
Newer Non-Statin Drugs for Reducing Cholesterol   by  on 2010-04-13 15:57:20
Practice Guidelines for Chronic Pain Management   by  on 2010-04-05 04:52:16
CONSORT III (2010)   by  on 2010-03-29 20:53:28
US FDA Draft Guidance on Pharmacokinetics in Patients with Impaired Renal Function   by  on 2010-03-20 20:25:16
US-FDA issues First Draft Guidance on Noninferiority Trials   by  on 2010-03-04 22:07:46
US FDA new rule on reporting information regarding falsification of data   by  on 2010-02-26 04:47:33
US-FDA Guidance for the Use of Bayesian Statistics in Medical Device Clinical Trials   by  on 2010-02-06 20:12:14
 Subject :Comprehensive Feasibility.. 2009-10-14 00:50:43 
Sreedhar
Newbie
Joined: 2009-10-09 16:27:58
Posts: 3
Location: 

 

  Hi

Comprehensive Feasibility?
Developing and utilizing a comprehensive feasibility strategy to avoid risk and ensure the most efficient clinical trial.

Yes, we need one...Clinical trial programs that commonly face unexpected delays and challenges are those that do not have a robust contingency plan and thus struggle to negotiate them in a timely fashion. A robust contingency plan will be incomplete if the outcomes from a well laid out comprehensive feasibility strategy does not form a part of it. So, developing and executing a comprehensive feasibility strategy is a vital step in the drug development life cycle, as it will not only enable the clinical developers to identify the risks but also recommend risk mitigation strategies very early on in the processWhy?Developing and incorporating a comprehensive feasibility strategy into the clinical development plan along with adequate allocation of time, budget, and resources is crucial for the success of a trial. This is more relevant and critical given the nature and complexity of trials in the current competitive landscape, especially for global programs. This could be one of the defining criteria for the successful execution of a clinical trial program. It will enable clinical scientists and program managers to identify foreseen and unforeseen risks and develop strategies to mitigate them. Time and resourcesSubsequent to the development of a feasibility strategy, undertaking a successful feasibility exercise prior to the launch of a clinical trial or program is vital. Doing so provides an opportunity to address some of the critical unanswered or unvalidated questions that otherwise might not be addressed. It is important that adequate budget, timelines, and resources are devoted to the strategy so that clinical teams have time to utilize the resultant information and effect changes either in their program or the study protocol. The feasibility strategy should also anticipate potential changes, some of which may have a major impact, including on the design of the protocol. Thus, a comprehensive feasibility strategy conducted within a realistic and executable period of time that employs appropriate resources, can make all the difference in a clinical trial. Collaborative inputDeveloping a comprehensive feasibility strategy should be a collaborative exercise between the clinical and feasibility teams. Utmost care should be applied during development to make sure it addresses all key objectives of the program. The feasibility teams, with support from their clinical and cross-functional colleagues, should be able to generate a comprehensive strategy to address potential foreseen and unforeseen risks. Given the elaborate and extensive nature of these exercises, input from other functional teams such as medical, regulatory, and reimbursement is also critical and should be included as part of the overall feasibility strategy. Investing in this type of feasibility strategy will not only serve as a potential indicator of the viability of the clinical program, it will also be complementary to the contingency plan.

Developing and integrating a comprehensive feasibility strategy into the clinical development plan provides a great opportunity. Potential risks can be perceived and specific mitigation strategies developed well in advance. It's all about being proactive, not reactive.

 Regards

Dr.Tirunagari Sreedhar

 
  

 
IP Logged
Page # 


Powered by ccBoard